새로운 항암성 항생물질 DA-125의 심장독성에 대한 평가 = A Study on Cardiotoxicity of DA-125,a Now Anticancer Antibiotic

다국어 초록 (Multilingual Abstract)

DA-125, a new anthracycline antibiotic, showed antitumor activity against animal tumors and human tumors. Therefore we studied the cardiotoxic potential of DA-125 in hamsters and rats as a part of safety research, and compared it with that of doxorubicin(DXR). In acute cardiotoxicity test model used hamsters DA-125 was administered intravenously at a dose of 6, 9, 12 ㎎/㎏, and DXR at 3 ㎎/㎏ was given. The electrocardiogram(ECG) of hamsters was recorded for 30 minutes after administration. The DA-125 caused slight ECG alterations at a dose of 6 ㎎/㎏. At a dose of 12 ㎎/㎏ DA-125 induced moderate to remarkable changes in ECG like decrease of heart rate, widening of PR interval and QT interval, and A-V block in 3 out of 5 animals. The severity of ECG alteration at 12 ㎎/㎏ of DA-125 was similar to that at 3 ㎎/㎏ of DXR and these changes caused by DA-125 and DXR recovered within 10 minutes after injection. In chronic cardiotoxicity test model used rats, DA-125 was administered intravenously once a week for three weeks at a dose of 6, 9 ㎎/㎏ and DXR was given at a dose of 6 ㎎/㎏. Electrocardiogram was recorded every week from the start of administration to 2 weeks after the last administration and the animals were sacrificed for histological heart examination at 1 week or 2 weeks after the last administration. DA-125 did not cause any abnormal changes in ECG and in histological heart examination due to administration, but DXR caused widening of ST segment, QRS complex, and QT interval from 1 week after administration and these changes were continued to necropsy. These alterations in ECG were accompanied by cardiac histological lesions such as vacuolation in myocardiac cells, interstitial edema and necrosis of myocytes. These results suggest that DA-125 is less cardiotoxic than DXR.